Novartis secures first-of-a-kind haematology approval
European Pharmaceutical Review
DECEMBER 6, 2023
The US Food and Drug Administration (FDA) has approved the first oral monotherapy treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH). Novartis’ Factor B inhibitor, Fabhalta ® (iptacopan) provides comprehensive control of red blood cell (RBC) destruction, according to the company. percent for anti-C5.
Let's personalize your content